Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00562809 · ClinicalTrials.gov registry record · Phase 4
The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,005
- Enrollment target
NCT00562809: Completed Phase 4 study, sponsored by Sanofi.
NCT00562809 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 1,005 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00562809, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,005 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of Irbesartan 150/12.5 mg and 300/25 mg in patients with hypertension not controlled by monotherapy.
Interventions
- DRUG IRBESARTAN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,005 participants |
| Start Date | 2003-07 |
| Est. Completion | 2004-08 |
| Phase | Phase 4 |
What the finished NCT00562809 record still lists
NCT00562809 is an interventional study that assigns participants to a tested intervention. Its 1,005 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% higher).
The record links to 0 conditions, and to 1 intervention - of which IRBESARTAN is the first listed.
NCT00562809 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00562809 about?
NCT00562809 is a clinical study titled "The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension". The purpose of this study is to assess the efficacy and safety of Irbesartan 150/12.5 mg and 300/25 mg in patients with hypertension not controlled by monotherapy.
What is the current status of trial NCT00562809?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,005 participants. The study started on 2003-07. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00562809?
The interventions under investigation include: IRBESARTAN (DRUG).
Who is sponsoring clinical trial NCT00562809?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00562809's enrollment target sits among peer trials
1,005 66th of 2000 higher than 1,935 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia